Completed
Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®
NCT01195454
- Conditions
- Autoimmune Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 1, +6 more
- Locations
-
- Sanofi-Aventis Administrative Office Berlin, Germany